about
Prediction of endometrial carcinoma by subjective endometrial intraepithelial neoplasia diagnosisPrognostic value of proliferation in invasive breast cancer: a reviewProliferation is the strongest prognosticator in node-negative breast cancer: significance, error sources, alternatives and comparison with molecular prognostic markersBiopsy histomorphometry predicts uterine myoinvasion by endometrial carcinoma: a Gynecologic Oncology Group study.The framework of pathology: good laboratory practice by quantitative and molecular methods.Confocal DNA cytometry: a contour-based segmentation algorithm for automated three-dimensional image segmentation.Prognostic value of gene signatures and proliferation in lymph-node-negative breast cancerPrediction of spontaneous regression of cervical intraepithelial neoplasia lesions grades 2 and 3 by proteomic analysisBiologic profiling of lymph node negative breast cancers by means of microRNA expression.The management of borderline epithelial tumors of the ovary.Consistent condom use increases the regression rate of cervical intraepithelial neoplasia 2-3.Can proliferation biomarkers reliably predict recurrence in World Health Organization 2003 defined endometrial stromal sarcoma, low grade?The prognostic value of mitotic activity index (MAI), phosphohistone H3 (PPH3), cyclin B1, cyclin A, and Ki67, alone and in combinations, in node-negative premenopausal breast cancer.Low- and high-risk CIN 1 and 2 lesions: prospective predictive value of grade, HPV, and Ki-67 immuno-quantitative variables.Prospective multicenter validation confirms the prognostic superiority of the endometrial carcinoma prognostic index in international Federation of gynecology and obstetrics stage 1 and 2 endometrial carcinoma.Comparative genomic hybridisation divides retinoblastomas into a high and a low level chromosomal instability group.Proliferation markers and DNA content analysis in urinary bladder TaT1 urothelial cell carcinomas: identification of subgroups with low and high stage progression risks.Dynamic behavioural interpretation of cervical intraepithelial neoplasia with molecular biomarkers.Genomics and proteomics--the way forward.Prediction of the anti-inflammatory mechanisms of curcumin by module-based protein interaction network analysisValidation of expression patterns for nine miRNAs in 204 lymph-node negative breast cancers.Benign endometrial hyperplasia sequence and endometrial intraepithelial neoplasia.Genomics and proteomics in neoplasia.Cervical intraepithelial neoplasia grade 3 lesions can regress.Squamous morules are functionally inert elements of premalignant endometrial neoplasia.Reproducibility and prognostic value of WHO1973 and WHO2004 grading systems in TaT1 urothelial carcinoma of the urinary bladder.Prognostic value of the diagnostic criteria distinguishing endometrial stromal sarcoma, low grade from undifferentiated endometrial sarcoma, 2 entities within the invasive endometrial stromal neoplasia family.Phosphohistone H3 expression has much stronger prognostic value than classical prognosticators in invasive lymph node-negative breast cancer patients less than 55 years of age.Digital image analysis improves the quality of subjective HER-2 expression scoring in breast cancer.Validating the prognostic value of proliferation measured by Phosphohistone H3 (PPH3) in invasive lymph node-negative breast cancer patients less than 71 years of age.Evaluation of 5 different labeled polymer immunohistochemical detection systems.Comparison of the effect of different techniques for measurement of Ki67 proliferation on reproducibility and prognosis prediction accuracy in breast cancer.Prognostic comparison of the proliferation markers (mitotic activity index, phosphohistone H3, Ki67), steroid receptors, HER2, high molecular weight cytokeratins and classical prognostic factors in T₁₋₂N₀M₀ breast cancer.Centromeric chromosomal translocations show tissue-specific differences between squamous cell carcinomas and adenocarcinomas.Advanced epithelial ovarian cancer: 1993 consensus statements.Molecular and biological factors in the pathogenesis of ovarian cancer.In Metastatic Non-small cell Lung Cancer Platinum-Based Treated Patients, Herbal Treatment Improves the Quality of Life. A Prospective Randomized Controlled Clinical Trial.Proposal for therapeutic approach based on prognostic factors including morphometric and flow-cytometric features in stage III-IV ovarian cancer.Quantitative molecular parameters to identify low-risk and high-risk early CIN lesions: role of markers of proliferative activity and differentiation and Rb availability.The additional prognostic value of morphometric nuclear arrangement and DNA-ploidy to other morphometric and stereologic features in endometrial hyperplasias.
P50
Q24647890-E9CF6BD4-B62B-44DA-BBE7-4205E19468C5Q24672660-79BFD95C-42B5-4747-9523-1EEFB17CACEAQ28289007-99E96F8D-A249-48DC-9622-C2AB169EADA8Q30439532-30D504B4-E4E7-4220-A5B7-EF54F53A6723Q30862047-839EA22C-B9A8-4BA3-9465-F9E5A39E9475Q31107968-514FC8C5-59EC-48E4-992E-22C240981491Q31152670-924DF21C-EE84-4958-A070-9A920A59FF54Q33849786-1A46B4EF-79D4-4909-BE15-F92122628775Q34136195-C06DC4F7-0315-4658-B724-F8819CA17823Q34176052-7C02EE5E-6423-4C08-88E0-5038265E89FCQ34428131-8CB7427E-4AD1-45C2-882A-F886874E549BQ35022506-6C60E87B-F8D9-497A-95FB-50F85EB8A982Q35064038-ED19AB29-6A6F-455C-8DCD-DE86AA670874Q35084779-D8B5B59E-209B-40F6-B2DA-204CC6E0BCA6Q35582706-C048F454-BCDF-4485-9CAE-B8C2BFDB7A82Q35586559-D2664F72-70F0-4002-BCB0-831B5B598E4AQ35586813-3A119056-3624-4024-8FE4-5DF85DEB79ECQ35774348-3FA0226C-0C62-41EF-B394-9886BD998714Q36164402-00EF13D8-1DC3-403B-84C1-2511E56EFC3DQ36363362-54A6D22B-DFC6-4010-A1B4-935E624F4822Q36381117-26CB6E58-B096-4DA5-92D4-F33914A1B710Q36783212-B7A68AFA-9DF6-4B8A-9B1C-535CD410366CQ36808837-1D99F05F-99E2-46A9-B45B-3C3DBF232637Q36808837-F02B277D-04FA-4FAF-8D1A-DD289D6988CAQ37053956-56902852-058E-4BF8-9AAC-E47C475BD7A1Q37078918-81D586C1-E8FD-474F-AF4A-65A03AF63880Q37444822-537451CD-6E58-44E4-8408-27F0F700DEE8Q38094886-EE3D4367-9848-420A-8412-68C729EDEB0EQ39816314-EC3A06A7-6EC0-4A35-9B0A-89A7171ADD24Q39830754-0C4196DB-A887-4339-9C5F-8F18344E2FA1Q39841101-1B54A468-0BA2-490A-A57E-39A9994F532EQ39895976-F113156D-0E6D-48BC-9123-BB075F854C2DQ40061893-1E1BA537-8BC0-45F4-8889-FE49A89EC2D0Q40107959-1518A7CD-1BD5-4CB7-B897-C163A6D010B5Q40464838-18C88BBD-3106-456D-A7E9-1690D0DF3FFCQ40816415-B3D32254-E9A5-49DC-BF73-422E486CC05AQ40816421-A63660C3-7B24-4B1A-BC07-079E3E5AE273Q41024097-96EC5CAF-1836-4AFA-A18B-8BC282CF3686Q41279256-9D787D65-0BFF-4CF7-B56E-9EA0CDD92A60Q42460214-3046CA19-617E-47A5-BA5E-41BA8E2C3F11
P50
description
Dutch oncologist
@en
Dutch oncologist
@en-ca
Dutch oncologist
@en-gb
Nederlands oncoloog
@nl
nederlansk onkolog
@nb
oncólogo neerlandés
@es
طبيب أورام هولندي
@ar
name
Johannes Pieter Albert Baak
@ast
Johannes Pieter Albert Baak
@da
Johannes Pieter Albert Baak
@de
Johannes Pieter Albert Baak
@en
Johannes Pieter Albert Baak
@es
Johannes Pieter Albert Baak
@fr
Johannes Pieter Albert Baak
@nb
Johannes Pieter Albert Baak
@nl
Johannes Pieter Albert Baak
@nn
Johannes Pieter Albert Baak
@sv
type
label
Johannes Pieter Albert Baak
@ast
Johannes Pieter Albert Baak
@da
Johannes Pieter Albert Baak
@de
Johannes Pieter Albert Baak
@en
Johannes Pieter Albert Baak
@es
Johannes Pieter Albert Baak
@fr
Johannes Pieter Albert Baak
@nb
Johannes Pieter Albert Baak
@nl
Johannes Pieter Albert Baak
@nn
Johannes Pieter Albert Baak
@sv
altLabel
Jan Baak
@en
Jan P. A. Baak
@nb
Jan PA Baak
@en
Johannes P. A. Baak
@nb
prefLabel
Johannes Pieter Albert Baak
@ast
Johannes Pieter Albert Baak
@da
Johannes Pieter Albert Baak
@de
Johannes Pieter Albert Baak
@en
Johannes Pieter Albert Baak
@es
Johannes Pieter Albert Baak
@fr
Johannes Pieter Albert Baak
@nb
Johannes Pieter Albert Baak
@nl
Johannes Pieter Albert Baak
@nn
Johannes Pieter Albert Baak
@sv
P735
P1006
P214
P1006
P2038
P21
P214
P2287
P31
P496
0000-0002-4018-9085
P569
1947-01-01T00:00:00Z
P7859
lccn-n82221235